Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.

about

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.

Item

http://www.wikidata.org/entity/Q55096281

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Concurrent miR-21 suppression ...... alcoholic fatty liver disease.

@en

Concurrent miR-21 suppression ...... alcoholic fatty liver disease.

@nl

type

Item

label

Concurrent miR-21 suppression ...... alcoholic fatty liver disease.

@en

Concurrent miR-21 suppression ...... alcoholic fatty liver disease.

@nl

prefLabel

Concurrent miR-21 suppression ...... alcoholic fatty liver disease.

@en

Concurrent miR-21 suppression ...... alcoholic fatty liver disease.

@nl

P1476

Concurrent miR-21 suppression ...... alcoholic fatty liver disease.

@en

P2093

Guilherme M Campos

http://www.w3.org/2001/XMLSchema#string

Guilherme S Mazzini

http://www.w3.org/2001/XMLSchema#string

Jad Khoraki

http://www.w3.org/2001/XMLSchema#string

Matthew G Browning

http://www.w3.org/2001/XMLSchema#string

P2860

Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice

Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression.

Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.

Targeting nuclear receptors for the treatment of fatty liver disease.

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.

Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.

P304

354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41419-018-0386-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29500352

http://www.w3.org/2001/XMLSchema#string

P932

5834452

http://www.w3.org/2001/XMLSchema#string